WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Other Events
ITEM8.01
| Other Events. |
On April11, 2017, WAVE Life Sciences Ltd. (the Company) issued a
press release announcing the commencement of an underwritten
public offering of ordinary shares to a shelf registration
statement filed on Form S-3 (File No.333-215428) with the
Securities and Exchange Commission, which was declared effective
on February6, 2017. In connection with the offering, the Company
also announced its intention to grant the underwriters an option
for a period of up to 30 days to purchase up to an additional 15%
of the number of ordinary shares sold in the offering on the same
terms and conditions. A copy of the press release is attached
hereto as Exhibit 99.1, and is incorporated herein by reference.
This Current Report on Form 8-K, including the Exhibit hereto,
shall not constitute an offer to sell or the solicitation of an
offer to buy any securities of the Company, which is being made
only by means of a written prospectus meeting the requirements of
Section10 of the Securities Act of 1933, as amended, nor shall
there be any sale of the Companys securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
| ITEM9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 |
Press release dated April11, 2017, announcing a proposed offering of ordinary shares. |
About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb. WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Recent Trading Information
WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) closed its last trading session down -0.20 at 26.55 with 10,169 shares trading hands.
